drugset / Trial / NCT03245489
Anti-platelet + Pembro for H&N Tumors
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2018-03-06
- Primary completion
- 2023-11-20
- Completion
- 2024-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | Oral |
| Subject | Clopidogrel | Small molecule | 75 mg | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |